Explain the implications of the implementation of Intellectual Property Clauses in our patent law regime after joining the WTO.
Show how India changed its patent regime to meet TRIPS obligations and analyse the consequences for medicines, industry, agriculture, traditional knowledge and innovation.
Common trap: Trace the change from the 1970 process-patent regime through the 1999, 2002 and 2005 amendments, then weigh the implications: access to medicines and generics, safeguards like Section 3(d) and compulsory licensing, and traditional knowledge and seeds.
SyllabusOld-pattern GS Paper I (2006–12): Current national issues — WTO and the Indian economy
Model answer
30 marks · 250-word limitIndia's Patents Act, 1970 allowed only process patents for food, medicines and chemicals, with short terms, which built a strong generic drug industry. As a founding WTO member in 1995 India had to comply with the TRIPS Agreement by 1 January 2005, leading to three amendments that reshaped its patent regime.
- 1970Patents Act: process patents only
- 1995WTO and TRIPS come into force
- 1999Mailbox and exclusive marketing rights
- 200220-year patent term
- 2005Product patents; Section 3(d)
- 2007Novartis challenge (later)
Changes made
- 1999 amendment: Introduced a mailbox for product patent applications and exclusive marketing rights, after the WTO upheld a US complaint in 1997.
- 2002 amendment: Set a uniform 20-year patent term, reversed the burden of proof in process cases and required disclosure of biological source material.
- 2005 amendment: Extended product patents to pharmaceuticals, food and chemicals, while adding pre- and post-grant opposition, Section 3(d) against evergreening and compulsory licences, including for export under the Doha flexibilities.
Implications
- Medicines: New patented drugs will be costlier and cheap copies of post-1995 molecules are barred, threatening India's role as the pharmacy of the developing world for HIV medicines.
- Pharmaceutical industry: Generic firms must shift to research, licensing and contract manufacturing; larger firms like Ranbaxy and Dr Reddy's gain from new R&D incentives and foreign collaboration.
- Innovation and FDI: Stronger protection is expected to attract foreign investment and research in biotechnology and software.
- Agriculture and traditional knowledge: Patents on life forms raised fears of biopiracy, as in the turmeric, neem and basmati cases; India responded with the PPV&FR Act (2001), the Biological Diversity Act (2002) and the Traditional Knowledge Digital Library.
- Wider IPR regime: The Geographical Indications Act (1999) protected products like Darjeeling tea, registered as India's first GI in 2004.
Balancing protection and access
- Use of flexibilities: India has used TRIPS flexibilities — strict patentability criteria, compulsory licensing and parallel imports — to protect public health.
- Need: Strong drug price control, public research funding and vigilance against patent abuse must accompany the new regime.
TRIPS compliance ended India's era of reverse engineering but, through careful drafting, India kept room for public health and traditional knowledge. (Later: the Supreme Court upheld Section 3(d) in the Novartis case in 2013, and India granted its first compulsory licence to Natco in 2012.)
Read more — sources
- OfficialThe Patents Act, 1970 and Patents (Amendment) Acts of 1999, 2002 and 2005
- OfficialWTO, Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and the Doha Declaration on TRIPS and Public Health (2001)
- BookRamesh Singh, Indian Economy — ch. on WTO and IPR
More from GS Paper I (old) 2006
Model answer by the EdiShorts editorial team. It is one well-argued treatment of the question, written to the official word limit — not an official UPSC answer key.